Next Article 
Infection and Immunity, December 1999, p. 6225-6233, Vol. 67, No. 12
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Increase of CD26/Dipeptidyl Peptidase IV Expression
on Human Gingival Fibroblasts upon Stimulation with Cytokines and
Bacterial Components
Eiji
Nemoto,1,*
Shunji
Sugawara,2
Haruhiko
Takada,2
Shigeru
Shoji,1 and
Hiroshi
Horiuch1
Department of Endodontics and
Periodontics1 and Department of
Microbiology and Immunology,2 Tohoku
University School of Dentistry, Sendai, 980-8575, Japan
Received 11 March 1999/Returned for modification 18 May
1999/Accepted 1 September 1999
 |
ABSTRACT |
CD26/dipeptidyl peptidase IV (DPPIV) is a cell surface ectoenzyme
which participates in immune and inflammatory reactions. We found that
CD26 was only partially expressed on human fibroblasts from periodontal
tissues, whereas fibroblasts from lung and skin expressed CD26
constitutively as revealed by flow cytometry. We examined the possible
upregulation of CD26 expression on human gingival fibroblasts in
response to various stimulants. Interleukin-1
(IL-1
); tumor
necrosis factor alpha; gamma interferon; lipopolysaccharide from
Porphyromonas gingivalis, Prevotella
intermedia, and Escherichia coli; and
Prevotella glycoprotein augmented CD26 expression on gingival fibroblasts. Among the stimulants, IL-1
exhibited the most
potent activity. Enzymatic activity of CD26 induced by IL-1
on
fibroblasts was determined colorimetrically in terms of Gly-Pro hydrolysis of a synthetic chromogenic substrate, Gly-Pro
p-nitroanilide. Among various inhibitors tested, diprotin A
and phenylmethylsulfonyl fluoride inhibited the enzymatic activity,
suggesting that the enzyme induced by IL-1
was DPPIV. The
upregulation of CD26 mRNA expression upon stimulation with IL-1
was
also revealed by a quantitative reverse transcription-PCR assay. In the
kinetic experiment, 48 h and several days were required for
maximum CD26 mRNA accumulation and CD26 molecule expression on the cell
surface, respectively. The addition of cycloheximide at 2 h before
IL-1
stimulation almost completely inhibited the accumulation of
CD26 mRNA. These results suggested that induction of CD26 on human
gingival fibroblasts is regulated at the transcriptional level and is
also dependent on a de novo-synthesized protein factor(s).
 |
INTRODUCTION |
Fibroblasts are the predominant cell
type in the connective tissues of various organs. They are considered
to function in the support of frameworks by synthesis of extracellular
matrix such as collagens and in tissue turnover and repair. Recent
studies have suggested that fibroblasts actively participate in
inflammatory and immune responses. Fibroblasts produce various
inflammatory cytokines such as interleukin-1 (IL-1) and IL-6 and
chemokines such as IL-8, which in turn influence other cells (30,
31, 33, 34), and conversely, fibroblasts are regulated by
inflammatory cytokines such as IL-1, tumor necrosis factor alpha
(TNF-
), and gamma interferon (IFN-
), as well as bacterial
components (8, 23, 26). Furthermore, fibroblasts are known
to be heterogeneous in function and morphology (7).
Recently, it has been reported that cell surface ectoenzymes play an
important role in inflammatory and immunological responses and in cell
differentiation by extracellular degradation or modification of
biologically active peptides, cytokines, and other cell surface proteins (16, 28). CD26 is a cell surface ectoenzyme,
dipeptidylpeptidase IV (DPPIV) (EC 3.4.14.5), and is a highly
glycosylated type II membrane sialoglycoprotein comprising two
identical subunits of approximately 110 kDa. CD26/DPPIV has a unique
specificity: it cleaves dipeptides from the N terminus of a polypeptide
if proline is at the penultimate position. Peptides are also cleaved if
alanine or hydroxyproline occupies the next (P1) position
(28). Since N termini containing Xaa-Pro are not easily
cleaved by other proteinases, the action of DPPIV is a rate-limiting
step in the degradation of polypeptides. The only other proteinase with
a similar specificity, DPPII (EC 3.4.14.2), has a lysosomal
localization (6). CD26/DPPIV was originally characterized as
a T-cell differentiation antigen and was reported to be expressed on
various cell types, such as renal proximal tubules, intestinal
epithelial cells, biliary caniliculae, alveolar pneumocytes, and skin
fibroblasts (6, 28).
Many biologically active polypeptides have the sequence Xaa-Pro at the
N terminus; therefore DPPIV may be essential for determining their
biological half-lives. These substrates include substance P, chorionic
gonadotropin, monomeric fibrin, and several releasing hormones which
could regulate the biological reactions (40). Recently, it
was reported that CD26/DPPIV was able to induce the N-terminal
truncation of several chemokines, including RANTES (for regulated on
activation, normal T-cell expressed and secreted) and stromal
cell-derived factor-1 (SDF-1). CD26-mediated processing of these
chemokines resulted in the alteration of chemokine receptor specificity
(19) or abrogation of chemotactic activities
(27). Furthermore, truncated RANTES inhibited infection of
mononuclear cells by a macrophage-tropic human immunodeficiency virus
type 1 (HIV-1) strain (19, 21). In contrast to truncated
RANTES, truncated SDF-1 diminished the potency to inhibit HIV-1
infection (27). These findings suggest that CD26/ DPPIV
regulates inflammatory and immunological responses.
In this study, we compared CD26/DPPIV expression in various human
fibroblasts from different tissues. We found that fibroblasts from
periodontal tissues only partially expressed CD26/DPPIV on their
surfaces, in contrast to those from skin and lung, which expressed this
molecule constitutively. We then investigated possible upregulation of
CD26/DPPIV expression on human gingival fibroblasts (HGF) in response
to inflammatory cytokines and cell surface components from periodontal
disease-associated bacteria. We also investigated the characteristics
of this enzyme and the regulatory mechanisms, and we discuss possible
involvement of the enzyme in the pathogenesis of periodontal diseases.
 |
MATERIALS AND METHODS |
Reagents.
Glycyl-prolyl p-nitroanilide
(Gly-Pro-pNA), p-nitroanilide (pNA),
diprotin A, phorbol 12-myristate 13-acetate (PMA), phenylmethylsulfonyl fluoride (PMSF), leupeptin, pepstatin A, bestatin, aprotinin, 1,10-phenanthroline, bovine serum albumin (BSA), and cycloheximide (CHX) were obtained from Sigma Chemical Co. (St. Louis, Mo.).
-Minimum essential medium (
-MEM) and 0.25% trypsin-1 mM EDTA were from Gibco BRL (Rockville, Md.). Fetal calf serum (FCS) was obtained from Flow Laboratories (McLean, Va.). Anti-CD26 monoclonal antibody (MAb) (M-A261; mouse immunoglobulin G1 [IgG1]) was purchased from Pharmingen (San Diego, Calif.). Anti-CD14 MAb (MEM-18; mouse IgG1)
was purchased from Monosan (Uden, The Netherlands). Isotype control
antibody (Ab) (679.1Mc7; mouse IgG1) was purchased from Coulter (Miami,
Fla.). Human natural IFN-
(antiviral activity, 8.0 × 106 IU/mg of protein) was kindly provided by the
Hayashibara Bioscience Institute (Okayama, Japan). Human recombinant
IL-1
, anti-human IL-1
rabbit serum, and human recombinant TNF-
were obtained from Dainippon Pharmaceutical Co. Ltd. (Osaka, Japan).
Cells and cell culture.
HGF were prepared from the explants
of normal gingival tissues of 8- to 25-year-old patients, with informed
consent, as described previously (31). Human periodontal
ligament (PDL) fibroblasts were prepared from the root surfaces of
healthy human erupted third molars. Ligamental tissues were obtained by
scraping the root surface. Both explants were cut into pieces and
cultured in 100-mm-diameter tissue culture dishes (Falcon; Becton
Dickinson Labware, Lincoln Park, N.J.) in
-MEM supplemented with
10% FCS with a medium change every 3 days for 10 to 15 days until
confluent cell monolayers were formed. The cells were detached with
0.25% trypsin-1 mM EDTA, washed with phosphate-buffered saline (PBS), and subcultured in plastic flasks (Corning Coster, Acton, Mass.). After
three or four subcultures by trypsinization, homogeneous, slim,
spindle-shaped cells grown in characteristic swirls were obtained. The
cells were used as confluent monolayers at subculture levels 5 through
15. Human skin fibroblasts (SF-MA) and human lung fibroblasts (WI-38,
MRC-5, and IMR-90) were obtained from the Japanese Cancer Research
Resources Bank (Tokyo, Japan). Human skin fibroblasts (FS-4) were
generously supplied by M. Kohase, National Institute of Infectious
Diseases (Tokyo, Japan). These fibroblasts were maintained in
-MEM
supplemented with 10% FCS.
Preparations of bacterial components.
Lipopolysaccharide
(LPS) was prepared from Porphyromonas gingivalis 381 and
Prevotella intermedia ATCC 25611 by the hot phenol-water extraction method as described previously (14, 32). LPS was also extracted from P. intermedia ATCC 25611 by use of a
phenol-chloroform-petroleum ether mixture (PCP) (14). Hot
phenol-water-extracted LPS from Escherichia coli (O127:B8)
was purchased from Sigma Chemical Co. Prevotella
glycoprotein (PGP), which has been reported to show stimulatory
activity on HGF and to possess no Limulus activity, was
prepared as described previously (14). Fimbriae prepared from P. gingivalis 381 (18) were generously
supplied by T. Ogawa (Asahi University Dental School, Gifu, Japan).
Stimulation of fibroblasts.
Fibroblasts were cultured in
96-well multiplates for enzyme assay, in 24-well multiplates for flow
cytometry, and in 6-well multiplates for reverse transcription-PCR
(RT-PCR). The final volumes were 200 µl, 1 ml, and 5 ml of 10%
FCS-
-MEM, respectively. When the cultured cells were almost
confluent, the culture media were renewed and various stimulants were
added and then incubated for the indicated times.
Immunostaining.
Fibroblasts were collected by
trypsinization, washed with PBS (pH 7.2), and used for staining. To
determine the expression of CD26 and CD14, 105 fibroblasts
were incubated at 4°C for 30 min with 1 µg of anti-CD26 MAb
(M-A261) and anti-CD14 MAb (MEM-18) diluted in 0.1%
NaN3-0.1% BSA in PBS. After being washed twice with 0.1%
NaN3-0.1% BSA in PBS, the cells were stained with
fluorescein-conjugated goat anti-mouse Igs (Biosource International,
Camarillo, Calif.) at 4°C for a further 30 min and then washed twice
more. Staining was analyzed on a FACScan fluorescence-activated cell
analyzer (Becton Dickinson, Mountain View, Calif.). Data were collected
for 5,000 events, which were stored in list mode and then analyzed with
Lysis II software (Becton Dickinson).
Assay for DPPIV activity.
DPPIV activity was assayed by
using a chromogenic substrate, Gly-Pro-pNA, as described
previously (22). HGF (104) were seeded into
96-well flat-bottomed plates (Nunc, Roskilde, Denmark) in 200 µl of
-MEM with 10% FCS until confluent cell monolayers formed. Confluent
HGF were stimulated with various cytokines and bacterial components for
6 days before being washed with PBS three times and used for enzyme
assay. Proteolytic activity was determined by measurement of the amount
of pNA formed in the supernatant at 405 nm. The confluent
monolayer in the 96-well flat-bottomed plate was incubated at 37°C
for the indicated times with 2 mM Gly-Pro-pNA in 100 mM
HEPES buffer (pH 7.6) containing 0.12 M NaCl, 5 mM KCl, 1.2 mM
MgSO4, 8 mM glucose, and 10 mg of BSA per ml. The plate was
covered with an adhesive plate cover during the culture, and the final
volume of the incubation mixture was 100 µl. Tests were run in
triplicate; cell-free and substrate-free blanks were run in parallel.
The results were expressed as nanomoles of pNA formed per
hour per confluent-monolayer cell at 37°C. To examine the effects of
potential inhibitors, cells were preincubated with inhibitors for 15 min at 37°C before addition of the substrate to the incubation
mixture. To examine the effect of anti-CD14 MAb on DPPIV induction, the
HGF monolayer in the 96-well plate was incubated with dialyzed
anti-CD14 MAb (MY4, mouse IgG2b; Coulter) at 10 µg/ml or with
dialyzed isotype control mouse IgG2b (Becton Dickinson) at 10 µg/ml
at 37°C for 30 min. Antibody-treated cells were stimulated with 10 µg of E. coli LPS per ml for 6 days. To examine the effect
of anti-IL-1
Ab on DPPIV induction by LPS, the HGF monolayer in the
96-well plate was incubated with 10 µg of E. coli LPS per
ml for 6 days with addition of anti-IL-1
Ab at a 1:100 dilution at
days 0, 1, and 2.
Real-time quantitative PCR.
The RNAgents Total RNA Isolation
System (Promega Corporation, Madison, Wis.) was used for the extraction
of total RNA from cultured fibroblasts according to the manufacturer's
instructions. The application volume for RT-PCR was determined by
electrophoresis. RT and real-time quantitative PCR were performed
(9, 13) with use of EZ RT-PCR Core reagents (PE Applied
Biosystems, Foster City, Calif.). Briefly, 100 ng of RNA was subjected
to quantitative RT-PCR. The primers used for PCR had the following
sequences: forward primer, 5'-GCTTGTCACCATCATCACCGT-3', and
reverse primer, 5'-AGTGTAAGTTTTGCGACTGTCAGC-3'. The reaction
produced an 85-bp PCR product. The RT-PCR mixture (50 µl) contained
Taq Man buffer A, 12.5 U of Tth DNA polymerase, a 300 nM
concentration of each primer, 1.25 U of AmpliTaq Gold DNA polymerase,
5.5 mM MgCl2, 300 µM dATP, 300 µM dCTP, 300 µM dGTP,
and 600 µM dUTP. The reaction mixture contained the following
detection probe (200 nM):
5'-(FAM)TCTGCTGAACAAAGGCACAGATGATGCTAC(TAMRA)-3', where FAM
is 6-carboxyfluorescein and its emission spectrum is quenched by the
second fluorescent dye, TAMRA (6-carboxy-tetramethylrhodamine). The
nuclease degradation of the hybridization probe releases the quenching
of the FAM fluorescent emission, resulting in an increase in peak
fluorescent emission at 518 nm. All reactions were performed in an ABI
Prism 7700 sequence detector (PE Applied Biosystems), which allows
measurement of the fluorescent spectra of the 96 wells of the thermal
cycler continuously during PCR amplification. The thermal cycler
conditions were as follows: 35 cycles of denaturation at 94°C for
20 s, annealing at 55°C for 20 s, and extension at 72°C
for 30 s. Reaction conditions were programmed on a Mac Power PC
7200/120 linked directly to the model 7700 sequence detector. Analysis
of data was performed with ABI Prism 7200/7700 sequence detection
system software version 1.6.3. Briefly,
Rn (reporter dye
emission/quencher dye emission) was plotted on the y axis, and the PCR cycle number was plotted on the x axis. The
threshold was determined from the data points collected from the
baseline of the amplification plot. The point at which the
amplification plot crosses the threshold was defined as the Ct value
(cycle number at this point). Ct can be used as a quantitative
measurement of the input target number with 105-order
linearity. Because PCR products theoretically double in number every
cycle, the difference between the target number can be calculated to be
2x in the case that the difference of the Ct
value is x (9, 13).
Statistical analysis.
Most of the experiments were carried
out in triplicate assays. The statistical significance between two
means was analyzed by Student's unpaired t test. All
experiments in this study were repeated to test the reproducibility of
the results.
 |
RESULTS |
Expression of CD26/DPPIV on fibroblasts derived from various
organs.
CD26 expression on fibroblasts derived from various organs
was investigated by flow cytometry (Table
1). The number of cells expressing CD26
among fibroblasts from lung and skin was very high, with the averages
being 94.7 and 84.1%, respectively. These results were consistent with
previous reports (22) which stated that most dermal
fibroblasts (more than 70%) expressed CD26. However, few fibroblasts
from periodontal tissue (gingiva and periodontal ligaments) expressed
CD26, with the averages being 20.8 and 17.5%, respectively. The mean
fluorescence values were also correlated to the percent positivity of
CD26. It has been reported that the phenotypic characteristics of
fibroblasts depend on the organs or tissues from which the fibroblasts
are derived (1, 2, 29, 31). These results suggested organ
specificity in respect to CD26 expression on fibroblasts.
Induction of CD26 expression on the surface of HGF in response to
cytokines and bacterial components.
The difference in CD26
expression on fibroblasts between periodontal tissues and lung or skin
moved us to investigate whether CD26 expression was inducible on
periodontal tissue fibroblasts upon stimulation with various materials.
HGF and PDL fibroblasts were stimulated with IL-1
, PMA, IFN-
,
TNF-
, and E. coli LPS for up to 6 days and then stained
with anti-CD26 MAb for flow cytometry. Figure
1A shows that a marked increase of CD26
expression on HGF was observed upon stimulation with IL-1
compared
with controls at day 6 (78.1% expression after stimulation versus
31.2% for the control), and the other stimulants, i.e., PMA, IFN-
, TNF-
, and E. coli LPS, also upregulated the CD26
expression on HGF significantly (P < 0.05) compared
with the control at day 6 (50.5, 47.4, 48.7, and 44.2% expression,
respectively). In regard to the kinetics of CD26 expression upon
stimulation, the upregulation was a slow response, with expression
increasing gradually upon each stimulation and reaching a plateau at
around day 6 after stimulation. On the other hand, as shown in Fig. 1B,
only slight induction of CD26 expression on PDL fibroblasts was
observed upon stimulation with IL-1
and IFN-
. To represent the
amount of CD26 expression more accurately, the mean fluorescence
channel values of CD26 before stimulation and after stimulation for 6 days are shown in Table 2. The mean
fluorescence value and percent positivity of CD26 were almost
correlated. E. coli LPS did not exhibit activity on PDL
fibroblasts. It must be noted here that HGF expressed CD14 on the cell
surface at a high level, whereas PDL fibroblasts expressed it at a low
level (Table 1). These findings suggested the heterogeneity of
fibroblasts even within periodontal tissues. In the following studies,
HGF were used because of their high responsiveness.

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Induction of CD26 on cell surfaces of HGF and PDL
fibroblasts in response to various stimulants. Confluent HGF (donor,
YS-G) (A) and PDL fibroblasts (donor, AK) (B) were stimulated with
IL-1 (10 ng/ml), PMA (100 ng/ml), IFN- (200 U/ml), TNF- (40 ng/ml), or E. coli LPS (10 µg/ml) for the indicated times
(A) and for 6 days (B) in -MEM supplemented with 10% FCS. After
being harvested by trypsinization, cells were stained with anti-CD26
MAb and analyzed by fluorescence-activated cell sorting. The results in
panels A and B are representative of four different experiments with
four different donors (YS-G, NIK, AK-G, and KEK) and three different
experiments with three different donors (AK, TT, and YS), respectively.
Triplicate (A) and single (B) assays were carried out, and differences
from the control were significant at P < 0.01 (**)
and P < 0.05 (*).
|
|
CD26-associated DPPIV activity on HGF stimulated with cytokines and
bacterial components.
HGF were cultured for 6 days with or without
stimulants, and confluent-monolayer cells were subjected to DPPIV assay
with Gly-Pro-pNA as a substrate. Figure
2 shows that all stimulants induced the
enzymatic activities on HGF significantly (P < 0.01) compared with unstimulated HGF. Among the stimulants, IL-1
had the
most potent effect on the induction of DPPIV activity on HGF. Since
CD26 is an ectoenzyme, it is natural that this observation was
consistent with that of CD26 expression analyzed by flow cytometry (percent positivity and mean fluorescence value of CD26) (Fig. 1). It
has been reported that LPS from oral black-pigmented bacteria (BPB)
exhibits atypical biological activities, unlike the common LPS from
Enterobacteriaceae (11, 39). We examined the
response of HGF to various cell surface components from BPB in respect to DPPIV activity induction. Figure 3
shows that the phenol-water-extracted LPS from P. intermedia
and P. gingivalis induced the DPPIV activity with dose
dependency and that the activities were slightly weaker than those of
E. coli LPS. In contrast, the PCP-extracted LPS from
P. intermedia was scarcely active in induction of DPPIV
activity, whereas PGP exhibited a definite ability to induce DPPIV
activity. The activity of PGP was the strongest among the bacterial
components so far examined. P. gingivalis fimbriae, another
possible HGF activator, exhibited only weak activity at the highest
concentration (10 µg/ml). Gingival fibroblasts release IL-8 in
response to LPS in a CD14-dependent manner (31). We examined
whether the mechanism by which CD26/DPPIV is induced on gingival
fibroblasts after stimulation by LPS could depend on membrane CD14.
Figure 4 shows that anti-CD14 MAb (MY4)
only slightly inhibited the induction of CD26/DPPIV stimulated by LPS.
These results indicated that induction of CD26/DPPIV by LPS was in part
CD14 dependent.

View larger version (54K):
[in this window]
[in a new window]
|
FIG. 2.
Induction of DPPIV activity in HGF stimulated with
various stimulants. Confluent HGF (donor, MH-12) were stimulated with
IL-1 (10 ng/ml), PMA (100 ng/ml), IFN- (200 U/ml), TNF- (40 ng/ml), or E. coli LPS (10 µg/ml) for 6 days in -MEM
supplemented with 10% FCS in 96-well plates and then washed with PBS
three times, and confluent-monolayer cells in the plates were examined
by DPPIV assay with Gly-Pro-pNA as a substrate. The results
are representative of four different experiments with four different
donors (MH-12, NIK, FE, and YS-G). Differences from the control were
significant at P < 0.001 (**) and P < 0.01 (*).
|
|

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 3.
Induction of DPPIV activity in HGF stimulated with
various bacterial components. Confluent HGF (donor, NIK) were
stimulated with various concentrations of bacterial components for 6 days in -MEM supplemented with 10% FCS in 96-well plates and then
washed with PBS three times, and confluent-monolayer cells in 96-well
plates were examined by DPPIV assay with Gly-Pro-pNA as a
substrate. E. coli LPS extracted with phenol-water, P. gingivalis (P.g.) LPS extracted with phenol-water,
P. intermedia (P.i.) LPS extracted with
phenol-water (PW), P. intermedia LPS extracted with PCP,
PGP, and P. gingivalis fimbriae were used. The results are
representative of two different experiments with two different donors
(NIK and AK-G). Differences from the control were significant at
P < 0.01 (**) and P < 0.05
(*).
|
|

View larger version (58K):
[in this window]
[in a new window]
|
FIG. 4.
Partial inhibition of LPS-induced CD26/DPPIV by
anti-CD14 MAb. Confluent HGF (donor, NIK) were stimulated with E. coli LPS (10 µg/ml) for 6 days along with anti-CD14 MAb (MY4; 10 µg/ml) or isotype control mouse IgG2b (10 µg/ml), and then DPPIV
assay was performed. The results are representative of two different
experiments with two different donors (NIK and YS-G). Differences were
significant at P < 0.05 (*).
|
|
Characterization of CD26-associated DPPIV activity.
DPPIV was reported to be a serine protease (22),
and diprotin A (Ile-Pro-Ile) is specifically used to inhibit DPPIV
activity (37). We examined whether the enzyme expressed on
HGF stimulated with IL-1
was sensitive to such inhibitors. As shown
in Table 3, diprotin A strongly inhibited
Gly-Pro-pNA hydrolysis (88.2% inhibition). A serine
protease inhibitor, PMSF, inhibited Gly-Pro-pNA hydrolysis
partially. By flow cytometry, we also confirmed that 1 µM PMSF had no
effect on CD26 expression on gingival fibroblasts during 1 h of
culture (data not shown). The other inhibitors, bestatin
(aminopeptidase inhibitor), aprotinin (trypsin inhibitor), pepstatin A
(aspartic and acid protease inhibitor), leupeptin (serine and thiol
protease inhibitor), 1,10-phenanthroline (metalloprotease inhibitor),
and EDTA (metalloprotease inhibitor), had no effects on
Gly-Pro-pNA hydrolysis. Although DPPIV activity on HGF was low without stimulation, the activity on unstimulated HGF had a
sensitivity to inhibitors similar to that of IL-1-stimulated HGF (data
not shown). These results indicated that DPPIV activity was induced in
HGF in correlation with CD26 expression.
Cell surface DPPIV activity on HGF induced by IL-1
.
We
further examined whether the degradation of the substrate by the cell
suspension resulted from enzymatic activity of DPPIV on the cell
surface. It is possible that incorporation of a substrate by HGF
followed by intracellular degradation and release of pNA could occur or that intracellular enzymes were secreted. We carried out
the following experiments. IL-1
-stimulated HGF were incubated at
37°C for 1 h with the substrate, and then the supernatants were
harvested from monolayer cells. The harvested supernatants were
incubated for an additional 90 min without addition of any reagents,
and monolayer cells in enzyme assay buffer without substrate were
incubated for an additional 90 min. As shown in Fig.
5A, during this 90 min, the control group
(without separation of cells from substrate) exhibited an enzymatic
response that was linear and time dependent. On the other hand, neither
additional degradation of the substrate by the supernatant nor
pNA release from the cell suspension was observed during 90 min after the separation of cells from substrate. These results
excluded the possibility that the secretion of intracellular enzyme or
degradation of the substrate inside cells was responsible for the
degradation of the substrate in the cell suspension. Furthermore, the
possibility that enzymatic activity could be released by lysed cells
could be ruled out, since fewer than 3% of the cells died during the
experiment (Fig. 5B).

View larger version (20K):
[in this window]
[in a new window]
|
FIG. 5.
Cell surface enzyme is responsible for the degradation
of substrates by cells. (A) Confluent HGF (donor, MH-12) were
stimulated with IL-1 (10 ng/ml) for 6 days in -MEM supplemented
with 10% FCS in 96-well plates and then washed with PBS three times,
and confluent-monolayer cells were examined by DPPIV assay. Monolayer
cells were incubated with 2 mM substrate for DPPIV assay as described
in Materials and Methods. After a 60-min incubation, the supernatant
and the corresponding monolayer cells, which were resuspended in
peptidase medium, were incubated for an additional 90 min without
addition of the substrate. , pNA formed by intact
fibroblasts; , pNA formed by supernatant resulting from
60 min of preincubation of cells with the substrate; ,
pNA released by cells preincubated for 60 min with the
substrate. (B) The percentage of lysed fibroblasts was determined by
trypan blue exclusion at each time point. The results are
representative of three different experiments with three different
donors (MH-12, KEK, and NIK).
|
|
Induction of CD26/DPPIV mRNA expression in HGF in response to
IL-1
.
To determine whether the induction of CD26 by IL-1
was
due to a change in gene expression, as distinct from translation, posttranslational degradation, or modulation of the protein, the level
of CD26 mRNA was assessed by real-time quantitative PCR. Total RNA was
extracted from IL-1
-stimulated HGF at 0, 6, 12, 24, 48, and 96 h of culture. Table 4 shows the Ct value
(see Materials and Methods) at each point. Evaluation of the Ct value for the measurement makes it possible to quantify at the range of
105, compared with evaluation of the end point, which has a
linear range of two orders of magnitude (9, 13). Figure
6 shows the relative expression of CD26
mRNA in HGF for control cells and upon IL-1 stimulation. An increase in
CD26-specific mRNA was observed at 6 h (P < 0.001) after addition of IL-1
to the culture, reached a maximum
at 48 h, and decreased thereafter. Quantitative analysis of CD26
mRNA levels revealed an approximately 150-fold increase of CD26 mRNA
after 48 h of culture with IL-1
compared with the control. The
relative expression of CD26 mRNA was approximately 90-fold greater than
that of the control at 96 h. In the control culture without
stimulation, CD26 mRNA accumulation was scarcely observed during the
96 h. Thus, the changes in relative mRNA levels analyzed by
real-time quantitative PCR were consistent with the changes in protein
levels analyzed by flow cytometry.

View larger version (24K):
[in this window]
[in a new window]
|
FIG. 6.
Induction of CD26/DPPIV mRNA expression in response to
IL-1 in HGF. HGF (donor, NIK) were stimulated with or without
IL-1 (10 ng/ml) for the indicated times, and then total RNA was
extracted for real-time quantitative PCR. The Ct value is defined in
Materials and Methods. The relative difference in CD26 mRNA expression
was calculated according to the Ct value (Table 3). The relative value
of mRNA expression at day 0 was converted to 1. The results are
representative of two different experiments with two different donors
(NIK and FB). Differences from the respective controls were significant
at P < 0.001 (**) and P < 0.02
(*).
|
|
Induction of CD26 mRNA requires de novo protein synthesis.
When HGF were stimulated with IL-1
, the induction of CD26 at both
the mRNA and protein levels was slow (Fig. 1 and 6). These observations
raise the question of whether the CD26 mRNA requires de novo protein
synthesis for induction. We examined the effect of the protein
synthesis inhibitor CHX on IL-1-induced accumulation of CD26 mRNA in
HGF. Figure 7 shows that CHX (10 µg/ml)
added at 2 h before IL-1
blocked the induction of CD26 mRNA
completely, indicating that de novo protein synthesis was required for
CD26 mRNA induction.

View larger version (34K):
[in this window]
[in a new window]
|
FIG. 7.
Inhibition of CD26 mRNA accumulation in HGF by CHX. HGF
(donor, NIK) were preincubated with or without CHX (10 µg/ml) for
2 h and stimulated with or without IL-1 (10 ng/ml) for 24 h, and then the total RNA was extracted for real-time quantitative PCR.
The relative difference in CD26 mRNA expression was calculated
according to the Ct value as described in Materials and Methods. The
relative value of mRNA expression at day 0 was converted to 100%.
|
|
 |
DISCUSSION |
Since CD26 was identified as DPPIV in T cells, its biological
function has been investigated. In T cells, CD26 is capable of
transmitting signals to activate cytotoxicity, IL-2 secretion, and
proliferation (6). CD45 is comodulated with CD26 and is coprecipitated in T-cell lysates (36). Furthermore, CD26 was reported to bind to HIV-1 Tat protein (10). However, the
enzymatic activity is not absolutely required for such functions of
CD26. On the other hand, several functions which require the enzymatic activity have been postulated. For example, the proliferation of T
cells stimulated with mitogen was inhibited with a DPPIV-specific inhibitor (25), as was IL-2 and IFN-
production from T
cells (24). Other studies showed that substance P, chorionic
gonadotropin, monomeric fibrin, and several releasing hormones were
hydrolyzed by DPPIV (40). Recently, several chemokines,
including RANTES and SDF-1, which attract inflammatory cells to the
inflamed lesion, have been revealed to be substrates for CD26/DPPIV
(19, 27), and the specificity of chemokine receptors was
altered after degradation of chemokines by CD26/DPPIV, resulting in
regulation of inflammatory responses. Furthermore, alteration of the
specificity of truncated RANTES for chemokine receptor causes the
inhibition of HIV infection (19, 21). On the other hand,
truncated SDF-1 had diminished potency to inhibit HIV-1 infection
(27). These results suggested that CD26/ DPPIV actively
participates in inflammatory and immunological responses.
In this study, we first investigated whether CD26 was expressed on
fibroblasts from various tissues and the regulation of CD26 expression
on fibroblasts. Recent studies suggested that fibroblasts play an
important role in the regulation of inflammatory and immunological
responses as well as support frameworks for other cells (31, 33,
34); i.e., fibroblasts are able to function as antigen-presenting
cells in immunological reactions (8, 26), to produce
cytokines (such as IL-1, IL-6, TNF-
, and granulocyte-macrophage
colony-stimulating factor) and chemokines (such as IL-8, RANTES,
eotaxin, and monocyte chemoattractant protein-1) in inflammatory
responses (20, 30, 33, 34), and to express various adhesion
molecules upon activation (4). Here, we found that CD26 was
induced on gingival fibroblasts upon stimulation both at the protein
level as determined by flow cytometry (Fig. 1) and at the mRNA level as
determined by real-time quantitative RT-PCR (Fig. 6). In local
infection with periodontal disease-associated bacteria, HGF should be
exposed to inflammatory cytokines and various bacterial components. We
used cytokines (IL-1
, IFN-
, and TNF-
), a protein kinase C
activator (PMA), and bacterial components such as LPS fractions, PGP,
and fimbriae for activation of fibroblasts. All were able to induce
CD26/DPPIV on the cell surface. However, IL-1
had the most potent
effect for induction of CD26/DPPIV on the cell surface (Fig. 1A and 2).
Although bacterial components had less of an effect than IL-1
on the
induction, at a high concentration (10 µg/ml), bacterial components
significantly enhanced the induction. It has been reported that the
activities of LPS differed among sources, probably because of
differences in chemical structures (11, 39). In fact,
P. intermedia LPS (PCP extract) had practically no ability
to induce DPPIV, whereas the PGP fraction exhibited strong activity.
The phenol-water-extracted LPSs tested here apparently exhibited
similar activity with regard to the induction of DPPIV activity. It is possible, however, that the activity of phenol-water-extracted LPSs
from P. gingivalis and P. intermedia in this
study was derived mainly from PGP in the LPS fraction, as suggested by
Iki et al. (14). If so, the activity of the BPB LPS by
itself was considerably weaker than that of E. coli LPS. The
HGF used in this study generally expressed membrane CD14 (mCD14) on the
cell surface at high levels. A recent report by Sugawara et al.
(31) demonstrated that E. coli LPS activated HGF
to release IL-8 in an mCD14-dependent manner. In this study, E. coli LPS activated HGF to induce CD26/DPPIV in an mCD14-dependent
manner in part (Fig. 4). This is also supported by the fact that PDL
fibroblasts expressing low levels of CD14 on the cell surface did not
respond to E. coli LPS for CD26 induction (Fig. 1B). Given
the previous report by Takada et al. (33) demonstrating that
BPB LPS induced cell-associated IL-1
in gingival fibroblasts in
culture, CD26/DPPIV may be induced by LPS in an autocrine manner. We
set up an experiment using anti-IL-1
Ab, which blocked the CD26/DPPIV induction stimulated by 1 ng of IL-1
per ml. Anti-IL-1
Ab had no effect on the CD26/DPPIV induction stimulated by 10 µg of
E. coli LPS per ml when added on days 0, 1, and 2 (data not
shown), suggesting that induction of CD26/DPPIV by LPS is not via
IL-1
in an autocrine manner.
We also showed that induction of CD26/DPPIV upon stimulation occurred
on the cell surfaces of fibroblasts (Fig. 5) by demonstrating that the
degradation of the substrate resulted from DPPIV activity on the cell
surface and not from activity inside the cells. Furthermore, we clearly
identified the enzyme induced on fibroblasts as DPPIV by experiments
using various inhibitors, among which diprotin A (Ile-Pro-Ile) and PMSF
(a serine protease inhibitor) inhibited the enzymatic activity (Table
3). DPPIV was reported to be a serine protease; thus, PMSF inhibited
DPPIV activity partially (17). Diprotin A is specifically
used to inhibit DPPIV activity (37), since diprotin A is a
tripeptide which cannot be hydrolyzed by DPPIV and which competes with
the substrate for the active site of DPPIV. These characteristics were
consistent with our results (Table 3). Interestingly, while CD26/DPPIV
was only partially expressed on HGF and PDL fibroblasts, the
fibroblasts from lung and skin expressed CD26/DPPIV on the cell surface
constitutively (Table 1). The CD26/DPPIV expression in HGF was
upregulated by various stimulants, whereas that in PDL fibroblasts was
only slightly upregulated (Fig. 1A). These findings are supported by
the evidence that fibroblasts differ in morphology and function within
or between tissues and/or organs (7). The findings in this
study further suggested that CD26/DPPIV on fibroblasts plays important
roles in inflammatory reactions and that these roles differ between organs.
Several days were required for the expression of CD26 on the cell
surface following stimulation (Fig. 1A). This slow response was also
demonstrated at the transcriptional level (a maximum at around 48 h) by real-time quantitative RT-PCR, an extremely sensitive technique
for quantifying mRNA; unlike other quantitative PCR methods, whose
linear dynamic range is approximately two orders of magnitude, this
method has a very large dynamic range of starting target molecule
determination (at least five orders of magnitude) (9, 13).
We demonstrated that the induction of CD26 mRNA was completely blocked
when cells were pretreated with CHX at 2 h before addition of the
inducer. This result suggested that the requirement of de novo protein
synthesis can be attributed to the slow response for induction of CD26
on the cell surface. It is of interest to identify the de
novo-synthesized protein which induces CD26 on the cell surface
directly, and investigations to find the protein are under way. This
slow induction of CD26 suggested that CD26 on fibroblasts in
periodontal tissue might function at a late stage of inflammation or to
repair the damaged tissues.
Different patterns of CD26/DPPIV expression on fibroblasts have been
reported for several diseases, such as rheumatoid arthritis, psoriasis,
lichen planus, and systemic sclerosis (2, 22). CD26/DPPIV is
downregulated on skin fibroblasts in vivo and in vitro in systemic
sclerosis (scleroderma), which is an autoimmune disease characterized
as fibroblast activation and endothelial cell damage (2,
29), leading to the overproduction of extracellular matrix and
the development of fibrotic lesions. On the other hand, CD26/DPPIV is
upregulated on fibroblasts in psoriasis and rheumatoid arthritis
(22), both of which are associated with inflammatory and
immunological characteristics in which extracellular matrix breakdown
is an important part of the disease process (12, 38). Specific DPPIV inhibitors suppress collagen-induced and
alkyldiamine-induced arthritis in vivo (35). In periodontal
tissue, CD26/DPPIV is localized in gingival tissue from chronic
periodontitis patients by immunohistochemical analysis (15).
The CD26/DPPIV level in gingival crevicular fluid correlates positively
with clinical indications of disease severity in untreated patients and
is reduced after periodontal treatment (3, 5).
These findings suggest that CD26/DPPIV on fibroblasts is associated
with the regulation of inflammatory and immunological responses by
regulation of chemokines and biologically active peptides or by binding
to the ligands on other cells and that it is possibly associated with
the onset and course of dermatological, rheumatic, and periodontal diseases.
 |
ACKNOWLEDGMENTS |
This work was supported in part by Grants-in-Aid for Scientific
Research (no. 10307053, 10470378, 09671843, and 09671943) and for
Encouragement of Young Scientists (no. 10771212) from the Ministry of
Education, Science, Sports and Culture, Japan.
We thank C. Hirata, A. Sugiyama, and J. Hatakeyama for providing
cultured human fibroblasts. We also thank D. Mrozek (Medical English
Service, Kyoto, Japan) for reviewing the paper.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Endodontics and Periodontics, Tohoku University School of Dentistry, 4-1 Seiryo-machi, Aoba-ku, Sendai, 980-8575, Japan. Phone:
81-22-717-8336. Fax: 81-22-717-8339. E-mail:
eiji{at}mail.cc.tohoku.ac.jp.
Editor:
J. R. McGhee
 |
REFERENCES |
| 1.
|
Agarwal, S.,
C. S. Chandra,
N. P. Piesco,
H. H. Langkamp,
L. Bowen, and C. Baran.
1998.
Regulation of periodontal ligament cell functions by interleukin-1 .
Infect. Immun.
66:932-937[Abstract/Free Full Text].
|
| 2.
|
Bou-Gharios, G.,
J. Osman,
A. Amanda,
P. Monoghan,
R. Vancheeswaran,
C. Black, and I. Olsen.
1995.
Expression of ectopeptidase in scleroderma.
Ann. Rheum. Dis.
54:111-116[Abstract/Free Full Text].
|
| 3.
|
Cox, S. W., and B. M. Eley.
1992.
Cathepsin B/L-, elastase-, tryptase-, trypsin- and dipeptidylpeptidase IV-like activities in gingival crevicular fluid: a comparison of levels before and after basic periodontal treatment of chronic periodontitis patients.
J. Clin. Periodontol.
19:333-339[Medline].
|
| 4.
|
Dustin, M. L.,
R. Rothlein,
A. K. Bhan,
C. A. Dinarello, and T. A. Springer.
1986.
Induction by IL1 and interferon- : tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1).
J. Immunol.
137:245-254[Abstract].
|
| 5.
|
Eley, B. M., and S. W. Cox.
1992.
Cathepsin B/L-, elastase-, tryptase-, trypsin- and dipeptidylpeptidase IV-like activities in gingival crevicular fluid: correlation with clinical parameters in untreated chronic periodontitis patients.
J. Periodont. Res.
27:62-69[Medline].
|
| 6.
|
Fleischer, B.
1994.
CD26: a surface protease involved in T-cell activation.
Immunol. Today
15:180-184[Medline].
|
| 7.
|
Fries, K. M.,
T. Blieden,
R. J. Looney,
G. D. Sempowski,
M. R. Silvera,
R. A. Willis, and R. P. Phipps.
1994.
Evidence of fibroblast heterogeneity and the role of fibroblast subpopulations in fibrosis.
Clin. Immunol. Immunopathol.
72:283-292[Medline].
|
| 8.
|
Geppert, T. D., and P. E. Lipsky.
1985.
Antigen presentation by interferon- -treated endothelial cells and fibroblasts: differential ability to function as antigen presenting despite comparable la expression.
J. Immunol.
135:3750-3762[Abstract].
|
| 9.
|
Gibson, U. E. M.,
C. A. Heid, and P. M. Williams.
1996.
A novel method for real time quantitative RT-PCR.
Genome Res.
6:995-1001[Abstract/Free Full Text].
|
| 10.
|
Gutheil, W. G.,
M. Subramanyam,
G. R. Flentke,
D. G. Sanford,
E. Munoz,
B. T. Huber, and W. W. Bachovchin.
1994.
Human immunodeficiency virus 1 Tat binds to dipeptidylaminopeptidase IV (CD26): a possible mechanism for Tat's immunosuppressive activity.
Proc. Natl. Acad. Sci. USA
91:6594-6598[Abstract/Free Full Text].
|
| 11.
|
Hamada, S.,
H. Takada,
T. Ogawa,
T. Fujiwara, and J. Mihara.
1990.
Lipopolysaccharides of oral anaerobes associated with chronic inflammation: chemical and immunomodulating properties.
Int. Rev. Immunol.
6:247-261[Medline].
|
| 12.
|
Harris, E. D.
1990.
Rheumatoid arthritis. Pathophysiology and implications for therapy.
N. Engl. J. Med.
322:1277-1289[Medline].
|
| 13.
|
Heid, C. A.,
J. Stevens,
K. J. Livak, and P. M. Williams.
1996.
Real time quantitative PCR.
Genome Res.
6:986-994[Abstract/Free Full Text].
|
| 14.
|
Iki, K.,
K. Kawahara,
S. Sawamura,
R. Arakaki,
T. Sakuta,
A. Sugiyama,
H. Tamura,
T. Sueda,
S. Hamada, and H. Takada.
1997.
A novel component different from endotoxin extracted from Prevotella intermedia ATCC 25611 activates lymphoid cells from C3H/HeJ mice and gingival fibroblasts from humans.
Infect. Immun.
65:4531-4538[Abstract].
|
| 15.
|
Kennett, C. N.,
S. W. Cox, and B. M. Eley.
1996.
Histochemical and immunocytochemical localization of dipeptidyl peptidases II and IV in human gingiva.
J. Periodontol.
67:846-852[Medline].
|
| 16.
|
Kenny, A. J.,
M. J. O'Hare, and B. A. Gusterson.
1989.
Cell-surface peptidases as modulators of growth and differentiation.
Lancet
30:785-787.
|
| 17.
|
McDonald, J. K., and C. Schwabe.
1977.
Intracellular exopeptidases, p. 311-391.
In
A. J. Barrett (ed.), Proteinases in mammalian cells and tissues. Elsevier/North-Holland Biomedical Press, Amsterdam, The Netherlands.
|
| 18.
|
Ogawa, T.,
H. Shimauchi, and S. Hamada.
1989.
Mucosal and systemic immune responses in BALB/c mice to Bacteroides gingivalis fimbriae administered orally.
Infect. Immun.
57:3466-3471[Abstract/Free Full Text].
|
| 19.
|
Oravecz, T.,
M. Pall,
G. Roderiquez,
M. D. Gorrell,
M. Ditto,
N. Y. Nguyen,
R. Boykins,
E. Unsworth, and M. A. Norcross.
1997.
Regulation of the receptor specificity and function of the chemokine RANTES (Regulated on Activation, Normal T Cell Expressed and Secreted) by dipeptidyl peptidase IV (CD26)-mediated cleavage.
J. Exp. Med.
186:1865-1872[Abstract/Free Full Text].
|
| 20.
|
Patil, R. R., and R. F. Borch.
1995.
Granulocyte-macrophage colony-stimulating factor expression by human fibroblasts is both upregulated and subsequently downregulated by interleukin-1.
Blood
85:80-86[Abstract/Free Full Text].
|
| 21.
|
Proost, P.,
I. D. Meester,
D. Schols,
S. Struyf,
A. M. Lambeir,
A. Wuyts,
G. Opdenakker,
E. D. Clercq,
S. Scharpe, and J. V. Damme.
1998.
Amino-terminal truncation of chemokines by CD26/dipeptidyl-peptidase IV.
J. Biol. Chem.
273:7222-7227[Abstract/Free Full Text].
|
| 22.
|
Raynaud, F.,
B. Bauvois,
P. Gerbaud, and D. Evain-Brion.
1992.
Characterization of specific proteases associated with the surface of human skin fibroblasts, and their moduration in pathology.
J. Cell. Physiol.
151:378-385[Medline].
|
| 23.
|
Schmidt, J. A.,
S. B. Mizel,
D. Cohen, and I. Green.
1982.
Interleukin 1, a potential regulator of fibroblast proliferation.
J. Immunol.
128:2177-2182[Medline].
|
| 24.
|
Schon, E.,
H. U. Demuth,
E. Eichmann,
H. J. Horst,
I. J. Korner,
J. Kopp,
T. Mattern,
K. Neubert,
F. Noll,
A. J. Ulmer,
A. Barth, and S. Ansorge.
1989.
Dipeptidyl peptidase IV in human T lymphocytes. Impaired induction of interleukin 2 and interferon due to specific inhibition of dipeptidyl peptidase.
Scand. J. Immunol.
29:127-132[Medline].
|
| 25.
|
Schon, E.,
S. Jahn,
S. T. Kiessig,
H. U. Demuth,
K. Neubert,
A. Barth,
R. Von Baehr, and S. Ansorge.
1987.
The role of dipeptidyl peptidase IV in human T lymphocyte activation. Inhibition and antibodies against dipeptidyl peptidase IV suppress lymphocyte proliferation.
Eur. J. Immunol.
17:1821-1826[Medline].
|
| 26.
|
Shimabukuro, Y.,
S. Murakami, and H. Okada.
1996.
Antigen-presenting-cell function of interferon -treated human gingival fibroblasts.
J. Periodontal Res.
31:217-228[Medline].
|
| 27.
|
Shioda, T.,
H. Kato,
Y. Tashiro,
M. Ikegawa,
E. E. Nakayama,
H. Hu,
A. Kato,
Y. Sakai,
H. Liu,
T. Honjo,
A. Nomoto,
A. Iwamoto,
C. Morimoto, and Y. Nagai.
1998.
Anti-HIV-1 and chemotactic activities of human stromal cell-derived factor 1 (SDF-1 ) and SDF-1 are abolished by CD26/dipeptidyl peptidase IV-mediated cleavage.
Proc. Natl. Acad. Sci. USA
95:6331-6336[Abstract/Free Full Text].
|
| 28.
|
Shipp, M. A., and A. T. Look.
1993.
Hematopoietic differentiation antigens that are membrane-associated enzymes: cutting is the key!
Blood
82:1052-1070[Free Full Text].
|
| 29.
|
Shiwen, X.,
R. Vancheeswaran,
G. Bou-Gharios,
M. J. O'Hare,
I. Olsen,
D. Abraham, and C. Black.
1995.
Scleroderma-derived human fibroblasts retain abnormal phenotypic and functional characteristics following retroviral transduction with the SV40 tsT antigen.
Exp. Cell Res.
220:407-414[Medline].
|
| 30.
|
Smith, R. S.,
T. J. Smith,
T. M. Blieden, and R. P. Phipps.
1997.
Fibroblasts as sentinel cells: synthesis of chemokines and regulation of inflammation.
J. Immunol.
151:317-322.
|
| 31.
|
Sugawara, S.,
A. Sugiyama,
E. Nemoto,
H. Rikiishi, and H. Takada.
1998.
Heterogeneous expression and release of CD14 by human gingival fibroblasts: characterization and CD14-mediated interleukin-8 secretion in response to lipopolysaccharide.
Infect. Immun.
66:3043-3049[Abstract/Free Full Text].
|
| 32.
|
Takada, H.,
H. Hirai,
T. Fujiwara,
T. Koga,
T. Ogawa, and S. Hamada.
1990.
Bacteroides lipopolysaccharides (LPS) induce anaphylactoid and lethal reactions in LPS-responsive and -nonresponsive mice primed muramyl dipeptide.
J. Infect. Dis.
162:428-434[Medline].
|
| 33.
|
Takada, H.,
J. Mihara,
I. Morisaki, and S. Hamada.
1991.
Induction of interleukin-1 and -6 in human gingival fibroblast cultures stimulated with Bacteroides lipopolysaccharides.
Infect. Immun.
59:295-301[Abstract/Free Full Text].
|
| 34.
|
Tamura, M.,
M. Tokuda,
S. Nagaoka, and H. Takada.
1992.
Lipopolysaccharides of Bacteroides intermedius (Prevotella intermedia) and Bacteroides (Porphyromonas) gingivalis induce interleukin-8 gene expression in human gingival fibroblast cultures.
Infect. Immun.
60:4932-4937[Abstract/Free Full Text].
|
| 35.
|
Tanaka, S.,
T. Murakami,
H. Sugiura,
K. Kawashima, and T. Sugita.
1997.
Suppression of arthritis by the inhibitors of dipeptidyl peptidase IV.
Int. J. Immunopharmacol.
19:15-24[Medline].
|
| 36.
|
Torimoto, Y.,
N. H. Dang,
E. Vivier,
T. Tanaka,
S. F. Schlossman, and C. Morimoto.
1991.
Coassociation of CD26 (dipeptidyl peptidase IV) with CD45 on the surface of human T lymphocytes.
J. Immunol.
147:2514-2517[Abstract/Free Full Text].
|
| 37.
|
Umezawa, H.,
T. Aoyagi,
K. Ogawa,
H. Naganawa,
M. Hamada, and T. Takeuchi.
1984.
Diprotin A and B, inhibitors of dipeptidyl aminopeptidase IV, produced by bacteria.
J. Antibiot. (Tokyo)
37:422-425[Medline].
|
| 38.
|
Valdimarsson, H.,
B. S. Baker,
I. Jonsdohir, and L. Fry.
1986.
Psoriasis: a disease of abnormal keratinocyte proliferation induced by T-lymphocytes.
Immunol. Today
7:256-259.
|
| 39.
|
Wilson, M.
1993.
Biological activities of lipopolysaccharide and endotoxin, p. 171-198.
In
H. N. Shah, D. Mayrand, and R. J. Genco (ed.), Biology of the species Porphyromonas gingivalis. CRC Press, Inc., Boca Raton, Fla.
|
| 40.
|
Yaron, A., and F. Naider.
1993.
Proline-dependent structural and biological properties of peptides and proteins.
Crit. Rev. Biochem. Mol. Biol.
28:31-81[Medline].
|
Infection and Immunity, December 1999, p. 6225-6233, Vol. 67, No. 12
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Kehlen, A., Lendeckel, U., Dralle, H., Langner, J., Hoang-Vu, C.
(2003). Biological Significance of Aminopeptidase N/CD13 in Thyroid Carcinomas. Cancer Res.
63: 8500-8506
[Abstract]
[Full Text]
-
Kajiyama, H., Kikkawa, F., Khin, E., Shibata, K., Ino, K., Mizutani, S.
(2003). Dipeptidyl Peptidase IV Overexpression Induces Up-Regulation of E-Cadherin and Tissue Inhibitors of Matrix Metalloproteinases, Resulting in Decreased Invasive Potential in Ovarian Carcinoma Cells. Cancer Res.
63: 2278-2283
[Abstract]
[Full Text]
-
Nemoto, E., Tada, H., Shimauchi, H.
(2002). Disruption of CD40/CD40 ligand interaction with cleavage of CD40 on human gingival fibroblasts by human leukocyte elastase resulting in down-regulation of chemokine production. J. Leukoc. Biol.
72: 538-545
[Abstract]
[Full Text]
-
Kajiyama, H., Kikkawa, F., Suzuki, T., Shibata, K., Ino, K., Mizutani, S.
(2002). Prolonged Survival and Decreased Invasive Activity Attributable to Dipeptidyl Peptidase IV Overexpression in Ovarian Carcinoma. Cancer Res.
62: 2753-2757
[Abstract]
[Full Text]
-
Nemoto, E., Sugawara, S., Tada, H., Takada, H., Shimauchi, H., Horiuchi, H.
(2000). Cleavage of CD14 on Human Gingival Fibroblasts Cocultured with Activated Neutrophils Is Mediated by Human Leukocyte Elastase Resulting in Down-Regulation of Lipopolysaccharide-Induced IL-8 Production. J. Immunol.
165: 5807-5813
[Abstract]
[Full Text]